Nasdaq granted KALA BIO, Inc. continued listing on The Nasdaq Capital Market, requiring a closing bid price of at least $1.00 per share from November 30, 2026 through February 23, 2027. The company had received a bid-price deficiency notice for July 16, 2026 through August 26, 2026.
KALA · KALA BIO, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 49%
- Last earnings
- Aug 8, 2025
- Latest filing
- 10-Q · Aug 19
- Price history
- Nov 2026 to Nov 2026
The closing range uses available history since Nov 16, 2026; less than a full year is stored.
Up next
Latest documents
KALA BIO, Inc. needs additional time to complete its analysis and disclosure regarding liquidity and capital resources for the quarter ended September 30, 2026, and expects to file no later than the fifth calendar day following the prescribed filing deadline.
KALA BIO will effect a 1-for-30 reverse stock split, reducing outstanding common shares from 19,339,786 to approximately 644,659; split-adjusted Nasdaq trading begins November 16, 2026 under KALA.
KALA BIO, Inc. reported preliminary third-quarter 2026 net loss of approximately $0.8 million, down from $7.6 million, and approximately $7.0 million in cash, cash equivalents and short-term investments with no debt.
KALA BIO, Inc. stockholders approved a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-300. The Board of Directors will determine the timing and publicly announce the selected ratio.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KALA
this stock
KALA BIO, Inc.
|
$1.74M | — | — | — | 2.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 30
Nasdaq granted KALA BIO, Inc. continued listing on The Nasdaq Capital Market, requiring a closing bid price of at least $1.00 per share from November 30, 2026 through February 23, 2027. The company had received a bid-price deficiency notice for July 16, 2026 through August 26, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KALA | — | — | — | — | — |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | — | — | — | — | — |